Personal CFO Solutions LLC lifted its stake in Chemed Co. (NYSE:CHE – Free Report) by 11.2% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 618 shares of the company’s stock after purchasing an additional 62 shares during the quarter. Personal CFO Solutions LLC’s holdings in Chemed were worth $328,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently modified their holdings of CHE. UMB Bank n.a. boosted its holdings in shares of Chemed by 300.0% in the 4th quarter. UMB Bank n.a. now owns 52 shares of the company’s stock worth $28,000 after purchasing an additional 39 shares during the period. Trust Co. of Vermont purchased a new position in shares of Chemed in the 4th quarter worth approximately $34,000. SRS Capital Advisors Inc. boosted its holdings in shares of Chemed by 39.2% in the 4th quarter. SRS Capital Advisors Inc. now owns 135 shares of the company’s stock worth $72,000 after purchasing an additional 38 shares during the period. Allworth Financial LP boosted its holdings in shares of Chemed by 2,057.1% in the 4th quarter. Allworth Financial LP now owns 151 shares of the company’s stock worth $83,000 after purchasing an additional 144 shares during the period. Finally, KBC Group NV boosted its holdings in shares of Chemed by 11.5% in the 3rd quarter. KBC Group NV now owns 378 shares of the company’s stock worth $227,000 after purchasing an additional 39 shares during the period. Hedge funds and other institutional investors own 95.85% of the company’s stock.
Chemed Stock Performance
Shares of CHE stock opened at $595.86 on Tuesday. Chemed Co. has a 52-week low of $512.12 and a 52-week high of $654.62. The firm has a market capitalization of $8.72 billion, a P/E ratio of 30.11, a P/E/G ratio of 2.15 and a beta of 0.43. The stock has a 50 day moving average price of $553.87 and a 200 day moving average price of $563.91.
Chemed Dividend Announcement
Wall Street Analyst Weigh In
Separately, StockNews.com upgraded Chemed from a “hold” rating to a “buy” rating in a report on Friday.
Insider Buying and Selling
In other news, VP Brian C. Judkins bought 145 shares of the firm’s stock in a transaction on Monday, December 30th. The stock was acquired at an average cost of $519.50 per share, with a total value of $75,327.50. Following the transaction, the vice president now directly owns 1,678 shares in the company, valued at approximately $871,721. This trade represents a 9.46 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Kevin J. Mcnamara sold 2,000 shares of Chemed stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $593.67, for a total value of $1,187,340.00. Following the sale, the chief executive officer now directly owns 102,679 shares of the company’s stock, valued at approximately $60,957,441.93. This trade represents a 1.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 3.32% of the stock is owned by corporate insiders.
Chemed Company Profile
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.
Further Reading
- Five stocks we like better than Chemed
- Learn Technical Analysis Skills to Master the Stock Market
- How to Protect Your Portfolio When Inflation Is Rising
- Using the MarketBeat Stock Split Calculator
- 3 Tech Stocks Defying Sector Weakness and Thriving in 2025
- Buy P&G Now, Before It Sets A New All-Time High
- Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors
Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Co. (NYSE:CHE – Free Report).
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.